Air quality alert issued for northern Minnesota due to Canada wildfire smoke
The Brief
The Minnesota Pollution Control Agency (MPCA) issued an air quality alert for northern Minnesota.
The alert is in place until Friday at 7 p.m.
Smoke from wildfires in Canada led to the alert being issued.
(FOX 9) - The Minnesota Pollution Control Agency (MPCA) has issued an air quality alert for areas in northern Minnesota.
What we know
An air quality was issued for the majority of northern Minnesota, and is in place until Friday at 7 p.m.
MPCA issued a red air quality alert, which is considered unhealthy for everyone, for areas including International Falls, Roseau, and the Tribal Nation of Red Lake.
There is an orange air quality alert, which is considered unhealthy for sensitive groups, for areas including Bemidji, East Grand Forks, Two Harbors, Hibbing, Ely, Duluth, and the Tribal Nations of Red Lake, Leech Lake, Grand Portage, and Fond du Lac.
For a full description of each air quality category, click here.
Dig deeper
In red air quality areas, wildfire smoke may make the sky look smoky, and the air look hazy. You may also smell smoke.
MPCA says this is unhealthy for everyone. Being outside could cause these symptoms: irritated eyes, nose, and throat, coughing, chest tightness, or shortness of breath.
Officials say to reduce outdoor activities, and reduce exposure.
Orange air quality areas will also make the sky look hazy, and residents may smell smoke.
This air quality is unhealthy for sensitive groups, and may aggravate heart and lung disease, and cardiovascular and respiratory conditions.
What you can do
To keep up to date on the air quality, click here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 hours ago
- CBS News
Midea recalls 1.7 million air conditioners over potential mold risk
Midea is recalling 1.7 million air conditioning units because a drainage problem could expose consumers to mold. Water can pool in the appliance maker's U Window Air Conditioner and U+ Window Air Conditioner units, possibly leading to mold growth, Midea said in a recall notice posted by the Consumer Product Safety Commission (CPSC). Mold can cause respiratory issues and other infections. The CPSC has received at least 152 reports from consumers of mold buildup in the Midea AC units, according to the alert. Of those, there have been 17 reports of users experiencing respiratory infections, allergic reactions, coughing and sneezing, or sore throats as a result of mold exposure. Along with the units sold in the U.S., nearly 46,000 were sold in Canada. The Midea products were sold under a range of brand names, including Comfort Aire, Danby, Frigidaire, Insignia, Keystone, LBG Products, Mr. Cool, Perfect Aire and Sea Breeze, according to the recall notice. A range of makes and models, measuring 22 inches wide by 14 inches high, are under recall (See the full list of affected model numbers.) The recalled air conditioners were sold at a variety of retailers, including Best Buy, Costco and Home Depot, from March 2020 through May of this year and retailed for between $280 and $500. Owners of the affected units are instructed to contact Midea for a full refund or a free repair. The company will provide a free shipping label for customers to send their units back to Midea. Alternatively, they can submit a photograph demonstrating that they have cut the unit's power cord to receive a refund.
New York Times
3 hours ago
- New York Times
Wildfire Smoke Brings More Hazardous Air Quality to Great Lakes and Beyond
As dozens of wildfires continued to burn across Canada on Friday, the country sat under a thick blanket of wildfire smoke, with some of that acrid air drifting into the United States. There are over 200 wildfires burning across Canada, with no end in sight to the outbreak. Air quality advisories and warnings have been issued across Canada, from British Columbia to Newfoundland. Follow the latest air quality and smoke information across Canada and the United States here. Smoke gets easily carried by winds. This week, it has drifted as far north as Newfoundland and as far south as Florida. 'There are some people who think this smoke could reach Europe,' said Stéphane Bilodeau, an adjunct professor specializing in air quality at McGill University in Quebec. Winnipeg, the provincial capital of Manitoba, and Fort Smith, a small town in the Northwest Territories, reported the worst air quality in Canada on Friday morning, with levels in the 'very high risk range,' according to the Canadian government. 'Today is the worst day in Montreal of this week,' Mr. Bilodeau said. 'Toronto has started to be very bad, too. 'The worst of all is definitely Winnipeg due to its proximity to the fires in Manitoba,' he added. 'It's just a couple miles from the core of the fires.' Air quality The impacts from smoke were less severe in the United States on Friday compared with previous days, especially in the Northeast, but Marc Chenard, a meteorologist with the Weather Prediction Center, said more smoke was expected to push into the country this weekend. 'There's another batch that could come down Saturday night into Sunday,' Mr. Chenard said. In the United States on Friday, the worst smoke impacts were over the Great Lakes, with the air quality in Detroit being 'very unhealthy,' between 100 and 140. The U.S. Environmental Protection Agency warns that wildfire smoke contains dangerous pollutants in the form of fine particles known as PM 2.5 that can penetrate deep into the lungs and enter the bloodstream. Short-term exposure can lead to bronchitis, worsen asthma and create other health issues. Peak wildfire season in Canada usually begins in June, but this year is proving to be an especially active start with fires growing large quickly. 'Definitely the start-up is a steep and severe one,' said Mr. Bilodeau. On Friday, there were 212 wildfires burning across Canada, with most of those in British Columbia, Alberta, Manitoba and Ontario, according to the Canadian Interagency Forest Fire Center.
Medscape
4 hours ago
- Medscape
Canagliflozin CV Benefits Appear to Be Dose-Dependent
Cardiovascular benefits associated with the SGLT2 inhibitor drug canagliflozin appear to be dose-dependent, with benefits in some key clinical endpoints — including mortality — observed only in the higher of the two key doses of 300 mg and 100 mg of the drug, new research shows. 'The benefit of canagliflozin on hard clinical endpoints may be dose-dependent, with the 300 mg dose showing a higher efficacy and a similar safety profile,' said first author Elias Elenjickal, MD, of the Research Institute of the McGill University Heath Centre, in Montreal, Quebec, in presenting the findings at the 62nd European Renal Association Congress 2025. Cardiovascular and renal benefits of SGLT2 inhibitor drugs are well established, and while dose-dependent effects have been reported in some pharmacokinetic studies, none — with the exception of the EMPA-REG OUTCOME trial (which was of empagliflozin) — have formally evaluated the impact of different doses on hard clinical endpoints, Elenjickal noted. To investigate whether dose indeed plays a role in those cardiovascular and renal endpoints with canagliflozin, Elenjickal and colleagues conducted a post-hoc analysis of the double-blind Canagliflozin Cardiovascular Assessment Study (CANVAS) study, which was part of the pivotal CANVAS Program. The CANVAS Program included the CANVAS and CANVAS-Renal studies. The results of the two trials were published together as part of the CANVAS program, not independently. The CANVAS study included 4330 patients with type 2 diabetes and a high cardiovascular risk, including known cardiovascular disease (CVD) or more than 2 risk factors for CVD. Those patients were randomized 1:1:1 to treatment with canagliflozin 100 mg, canagliflozin 300 mg, or placebo. Patients in the study had a median age of 61 years, 66% were male, and baseline characteristics between the groups were similar. With a mean follow-up of 74 months, those in the canagliflozin 300 mg group showed significantly greater reductions in the composite cardiovascular endpoint, including non-fatal myocardial infarction, stroke, or cardiovascular death, compared with placebo (hazard ratio [HR], 0.82; P = .04) after adjustment for factors including age, sex, and history of CVD. However, these differences were not observed between canagliflozin 100 mg and placebo for the composite endpoint (HR, 0.95; P = .55). There were no significant differences between the two canagliflozin doses and the incidence of the composite renal endpoint that included doubling of serum creatinine, end-stage kidney disease, or renal death, compared with placebo (HR, 0.48 for canagliflozin 100 mg; P = .03; HR, 0.41 for canagliflozin 300 mg; P = .01). Those in the 300 mg dose group were less likely to have progression of albuminuria to a higher stage (A1 to A2, or A2 to A3), compared with placebo (HR, 0.83; P = .006), but the difference was not significant with the 100 mg dose (HR, 0.94; P = .33). Importantly, all-cause mortality was significantly lower with the 300 mg dose compared with placebo (HR, 0.78; P =.03), while the 100 mg group only showed a trend toward lower mortality (HR, 0.89; P = .29). There were no significant differences between the two dose groups and placebo in terms of the incidence of acute kidney injury, while the 300 mg group had a trend towards fewer severe hyperkalemia episodes (adjusted HR, 0.61; P = .27). There were no differences observed in safety outcomes between the two dose groups or placebo. A Gender Difference? Of note, a further subgroup analysis showed an effect of gender on hospitalization rates for heart failure events: with males in the 300 mg group having a significantly decreased risk of heart failure hospitalization vs placebo (HR,.62), while females in the 300 mg group had an increased risk (HR, 1.72; P for interaction .03). In the 100 mg group, males also had a lower risk for heart failure hospitalization vs females (HR, 0.65 vs HR, 1.05; P for interaction .37). As a caveat, Elenjickal noted that males did have a higher burden of CVD at baseline (65% vs 46%). 'Overall, we found that canagliflozin 300 mg significantly reduced major adverse cardiac events, and reduction in all-cause mortality was observed only with a 300 mg dose: not with a 100 mg dose,' Elenjickal said. 'There is evidence of a dose-dependent effect with canagliflozin, which is unique among other SGLT2 inhibitors for hard clinical endpoints,' Elenjickal said. The CANVAS study was funded by Janssen Research and Development; number NCT01032629 . Elenjickal reported an educational grant from Pfizer.
